United Therapeutics reports Q2 EPS $5.24, consensus $4.50

Reports Q2 revenue $596.5M, consensus $524.17M. “I’m thrilled that United Therapeutics continues to report double-digit revenue growth and our highest quarterly revenue ever,” said Martine Rothblatt, Chairperson and CEO. “We expect this growth trajectory to continue with our current business as we expect to reach a $4B annual revenue run rate by mid-decade. Beyond that we expect continued waves of growth with an additional doubling of our revenue from the potential launch of Tyvaso in pulmonary fibrosis and ralinepag in pulmonary arterial hypertension, and then yet another doubling of our revenue with the potential for an unlimited supply of tolerable, transplantable organs in the next decade.”